TYSABRI
Active substance: natalizumab
INJECTION · NATALIZUMAB 300 mg/15mL
United StatesActive
Marketing holder: Biogen Inc.
Verified 2026-10-09 · openFDA NDC
Analogues in other countries- Source: openFDA NDC
- Countries with the substance registered: 2
Composition
- NATALIZUMAB · 300 mg/15mL
Analogues by country
Products with the same active substance registered in other countries.
| Country | Products |
|---|---|
| EU 3 |
|
Import and control
Control by country
- United Statesprescription only
Source: openFDA NDC · record 01a12090-7ef9-79bf-afbd-e3a97b071efe,01a12096-8726-704f-8bed-57167353f376;count=2 · valid from 2026-10-09 · verified 2026-10-09
Registration
- Registration number
- 64406-008
- Registration status
- Active
- Dispensing
- Prescription only
- Route
- INTRAVENOUS
Sources
- product · openFDA NDC · 64406-008 · Verified 2026-10-09 · open in source
- registration_status · openFDA NDC · 64406-008 · Verified 2026-10-09 · open in source
- ingredients.0 · openFDA NDC · 64406-008 · Verified 2026-10-09 · open in source